Skip to main content
. Author manuscript; available in PMC: 2012 Aug 9.
Published in final edited form as: Oncogene. 2011 Jul 18;31(6):716–727. doi: 10.1038/onc.2011.273

Figure 5. Membrane targeting of Vav3 eliminates Vav3 coactivation of AR.

Figure 5

A. PC3 cells were transfected with AR, PSA-luc, Vav3 or a Vav3-Kras fusion proteins containing Kras C-terminal membrane targeting sequence CAAX and treated with either vehicle or R1881 (5 nM). Samples were then assayed for luciferase activity and normalized to protein concentration. Data plotted as fold induction (± SEM) represent the average of 5 independent experiments performed in triplicate. Significance was determined by two-tailed Student’s t test (**p<0.01). B. Parallel cell cultures were subjected to western blot assay using anti-Vav3 and anti-actin antibodies.